Biomarker will improve accuracy of prognoses for cancer patients

Doctor and patient

Researchers at the Texas A&M Health Science Center ‘s Institute of Biosciences and Technology in Houston have identified a biomarker that will aid in more accurately determining the prognosis for prostate cancer patients, a finding that could have further implications for anti-cancer drug discovery and ultimately, cancer prevention.

The study, led by Leyuan Liu, Ph.D., assistant professor with the institute’s Center for Cancer and Stem Cell Biology, will appear in an upcoming edition of Cancer and is available online.

Based on data from tracking prostate cancer patients over a 10-year period, the latest research indicates a positive correlation between LRPPRC protein levels and tumor grade, cancer stage and prostate-specific antigen (PSA) level, as well as a negative correlation with response to hormone therapy treatment and overall survival.

More from the Texas A&M Health Science Center

#TAMUresearch

Share